PART I Overview We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development. Over more than two decades, we have developed and commercialized our proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001104659-26-034557 | EDGAR | 74K words |
| 2025-03-11 | 2024-12-31 | 0001558370-25-002721 | EDGAR | — |
| 2024-03-12 | 2023-12-31 | 0001558370-24-003001 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0001558370-23-003911 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001558370-22-004081 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001104659-25-111396 | EDGAR | 23K words |
| 2025-08-06 | 2025-06-30 | 0001558370-25-010554 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001558370-25-007005 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001558370-24-014662 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-011120 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007085 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018314 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014306 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001558370-23-009167 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017204 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013091 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001558370-22-007869 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001104659-26-036201 | EDGAR | 1K words |
| 2026-03-24 | 0001104659-26-033867 | EDGAR | — |
| 2026-03-20 | 0001104659-26-032761 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002901 | EDGAR | — |
| 2025-11-12 | 0001104659-25-110375 | EDGAR | — |
| 2025-11-05 | 0001104659-25-107118 | EDGAR | — |
| 2025-09-22 | 0001104659-25-092162 | EDGAR | — |
| 2025-08-11 | 0001558370-25-011056 | EDGAR | — |
| 2025-08-06 | 0001558370-25-010523 | EDGAR | — |
| 2025-06-25 | 0001558370-25-008856 | EDGAR | — |
75 total filings indexed. 48 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001287098 |
| Ticker | MXCT |
| Exchange | Nasdaq |
| SIC | 8731: Services-Commercial Physical & Biological Research |
| Incorporated | DE |
| Website | https://www.maxcyte.com |
| Listed | 2019-12-05 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/MXCT (~200 tokens, structured JSON with cryptographic provenance)